Pulmonary Circulation Diseases
Conditions
Brief summary
The purpose of this Clinical Research Collaboration is to investigate the prognostic implications of pulmonary hemodynamics during exercise based on a large scale multi-centre approach by using retrospective and prospective analysis of hemodynamic data.
Interventions
DIAGNOSTIC_TESTassessment of pulmonary hemodynamics during exercise by right heart catheterization
all patients undergo right heart catheterization during exercise due to clinical reasons. Results of this and other Routine clinical tests will be included in the registry
Sponsors
European Respiratory Society
Medical University of Graz
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients (females and males; age: above 18yrs) with intermediate or high echocardiographic probability of PH and/or unexplained dyspnea, and/or associated conditions for PAH as clinical indication for RHC at rest and exercise * Written informed consent of participating subjects after being fully briefed (for prospective analysis)
Exclusion criteria
* Patients with incomplete hemodynamic data at rest or exercise * Patients without sufficient follow-up data (information on survival / lung transplantation) * advanced tumour disease or other diseases with a short life expectancy, except pulmonary vascular diseases * advanced heart failure with pulmonary arterial wedge pressure (PAWP) \> 18 mmHg at rest * uncontrolled systemic arterial hypertension (RR values \> 160/100 mmHg at rest) * FEV1\<50% predicted * TLC\<60% predicted
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants who die during observation | 6 years | The investigators aim to assess the prognostic relevance of pulmonary hemodynamics during exercise as assessed by right heart catheterization by using a multi-centre approach and to identify independent predictors of adverse events. Separate data sets will be analysed for the retrospective and prospective Evaluation. |
| Number of Participants undergoing lung Transplantation during observation | 6 years | Occurrences of lung transplantations |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants being hospitalized during observation | 6 years | Number of hospitalizations |
| Number of Participants who develop pulmonary Hypertension as assessed by right heart catheterization | 6 years | Diagnosis of pulmonary hypertension |
| Number of Participants with newly initiated pulmonary arterial Hypertension medication during observation | 6 years | Evaluation of medication initiations |
Countries
Australia, Austria, Belgium, Brazil, Denmark, France, Germany, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom, United States
Contacts
Primary ContactGabor Kovacs, MD
Outcome results
None listed